Attached files

file filename
EX-99.1 - AMARANTUS BIOSCIENCE HOLDINGS, INC. PRESS RELEASE, DATED JANUARY 29, 2016. - Amarantus Bioscience Holdings, Inc.f8k012916ex99i_amarantus.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 29, 2016

 

 

 

AMARANTUS BIOSCIENCE HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   000-55016   26-0690857
(State or other jurisdiction
of incorporation or organization)
  (Commission File Number)  

IRS Employer

Identification No.)

 

655 Montgomery Street, Suite 900

San Francisco, CA

  94111
(Address of Principal Executive Offices)   (Zip Code)

 

(408) 737-2734

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

Item 8.01 Other Items.

 

On January 29, 2016, Amarantus Bioscience Holdings, Inc. (the “Company”) issued a press release announcing the issuance of Chinese patent number ZL2009801163060 entitled “Neurodegenerative Disorders” covering the use of MANF for the treatment of Parkinson’s disease and other neurodegenerative conditions.

 

A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
 99.1   Amarantus Bioscience Holdings, Inc. Press Release, dated January 29, 2016.

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  AMARANTUS BIOSCIENCE HOLDINGS, INC.
     
Date: January 29, 2016   By: /s/ Gerald E. Commissiong  
    Name: Gerald E. Commissiong  
    Title: Chief Executive Officer  

 

 

 3